915006-03-0

Upstream product

• 51605-97-1 2-bromo-4-isopropylaniline 
• 89490-05-1 cyclohex-1-enylboronic acid 
• 28075-50-5 cyclohex-1-en-1-yl trifluoromethane sulfonate 

Downstream Products

• 915006-04-1 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-isopropyl-phenyl)-amide 

Relevant academic research and scientific papers

A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice

Many clinical studies and epidemiological investigations have clearly demonstrated that women are twice as likely to develop cholesterol gallstones as men, and oral contraceptives and other estrogen therapies dramatically increase that risk. Further, anim

COMPOUNDS AND METHODS TARGETING GPER FOR TREATMENT OF DISEASES ASSOCIATED WITH CALCIUM

In one aspect, the present disclosure provides compounds of the formula (I): In other aspects, the present disclosure provides compositions and methods of targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease

COMPOUNDS AND METHODS TARGETING GPER IN CALCIUM DISORDERS

The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.

C-FMS KINASE INHIBITORS

The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.